Moderna and Merck Score Landmark Phase 3 Win With Personalized mRNA Cancer Vaccine

Key points

The Phase 3 INTerpath-001 trial evaluated 1,137 patients with stage IIB to IV cutaneous melanoma who had their tumors surgically removed ¹ ³.
Combining intismeran autogene (mRNA-4157/V940) with Merck's immunotherapy Keytruda successfully met its primary endpoint of recurrence-free survival, outperforming Keytruda alone ³ ⁴.
The treatment also hit its key secondary endpoint of distant metastasis-free survival, marking the first positive Phase 3 validation for a personalized neoantigen mRNA therapy ³ ⁴.
The breakthrough announcement triggered a massive short squeeze, causing shares of Moderna to skyrocket by roughly 131% in a single day and inflicting about $4.8 billion in losses on short sellers ⁴.

The Science of Custom mRNA

When a surgeon removes a melanoma tumor, it eliminates the visible mass, but it can never guarantee that every microscopic cancer cell has been cleared out ³. To address that lingering uncertainty, Moderna and Merck designed intismeran autogene – also known as mRNA-4157 or V940 – as a bespoke therapeutic vaccine ¹ ³ ⁴. The treatment relies on sequencing a patient’s unique tumor DNA, running computational algorithms to spot specific mutations called neoantigens, and manufacturing a customized mRNA sequence that instructs the body’s T cells to hunt down residual rogue cells ³ ⁴.

This patient-specific approach essentially bridges the gap between oncology and immunology by teaching the immune system to recognize tumor signals the same way it would spot a viral infection ¹ ³. Pairing this custom mRNA platform with Merck’s blockbuster immunotherapy Keytruda creates a two-pronged attack: the vaccine trains the immune system to spot the mutated targets, while Keytruda lifts the cellular brakes that allow cancer cells to hide from immune defenses ¹ ³ ⁴.

Landmark Trial Results

The companies put this personalized strategy to its toughest test yet in the double-blind Phase 3 INTerpath-001 trial, which enrolled 1,137 patients with stage IIB to IV melanoma who had undergone surgery but received no prior systemic therapy ¹ ³ ⁴. Patients were randomized to receive either the combination of intismeran and Keytruda or Keytruda alone, which represents the current standard of care ¹ ³ ⁴.

The trial met its primary endpoint by demonstrating a statistically significant improvement in recurrence-free survival (RFS) compared to the standard of care, alongside hitting key secondary endpoints like distant metastasis-free survival (DMFS) ³ ⁴. Although the formal hazard ratios and complete datasets are being reserved for an upcoming medical conference, earlier Phase 2b data had pointed to roughly a 49% reduction in the risk of recurrence or death and a 59% reduction in distant spread ¹ ³. Because the trial was halted early during its initial interim efficacy analysis, overall survival data remains immature and will take time to fully develop ³.

Market Rebound and Short Squeeze

The clinical milestone delivered a transformative financial and psychological boost to Moderna, which had faced sliding revenues and widespread layoffs following the post-pandemic decline of its COVID-19 vaccine franchise ¹. As the positive Phase 3 data crossed the wires, Moderna shares surged approximately 131% in a historic single-day move, trading near $148 after touching an intraday peak of $163, while partner Merck also enjoyed upward momentum ⁴.

The explosive rally caught heavily shorted positions off guard, leaving traders betting against the biotech with roughly $4.8 billion in mark-to-market losses ⁴. With short interest sitting around 13.5% of the company’s free float, the staggering jump triggered classic short-squeeze mechanics as frantic borrowers rushed to cover their positions and stop the financial bleeding ⁴.

Expanding Beyond Melanoma

With regulatory filings expected in the near future, the collaboration is looking far beyond skin cancer ¹ ³. Moderna and Merck are already conducting Phase 3 trials investigating intismeran in non-small cell lung cancer, while examining its potential across additional tumor types including kidney, pancreatic, and bladder cancers in multiple ongoing studies ¹ ³.

Company leadership believes the underlying mRNA platform can ultimately transform treatment paradigms across oncology ¹ ³. By intervening earlier in diseases like stage 1 lung cancer, researchers hope to prime the immune system before tumors spread widely, pointing toward a future where personalized cancer immunotherapies can be administered safely and efficiently with minimal toxicity compared to traditional treatments ¹.

Primary sources

Promising Results for mRNA Cancer Vaccine from Moderna and Merck (time.com) – Moderna and Merck's Phase 3 trial combining intismeran with Keytruda showed improved recurrence-free and distant-spread outcomes in melanoma patients, offering a vital boost to Moderna amid post-COVID financial challenges while fueling broader oncology trials.
Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here’s what’s happening (fastcompany.com) – Moderna shares more than doubled following the announcement that its personalized mRNA cancer vaccine met initial late-stage trial goals in combination with Keytruda.

Further sources

mRNA Cancer Vaccine Cuts Melanoma Recurrence in Landmark Phase 3 Trial (gadgetreview.com) – The INTerpath-001 trial successfully demonstrated that bespoke neoantigen mRNA therapy paired with Keytruda significantly cuts melanoma recurrence, paving the way for upcoming regulatory filings and multi-cancer expansion.
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means (decrypt.co) – Moderna stock skyrocketed roughly 131% to near $148 following the positive Phase 3 readout, triggering a massive short squeeze and causing nearly $4.8 billion in losses for short sellers.
Merck and Moderna's tailored cancer drug curbs melanoma recurrence in trial (medicalxpress.com) – A large clinical trial confirmed that an experimental personalized drug developed by Merck and Moderna successfully prevented melanoma from returning in patients.